SCOLR Pharma, Inc. is a specialty pharmaceutical company, which through its Controlled Delivery Technology (CDT) platforms, develops prescription, over-the-counter (OTC) and nutritional products. The Company has developed multiple private-label controlled release nutritional products incorporating its CDT platforms that are sold by national retailers. The Company’s lead product candidate is a CDT-based controlled release formulation of ibuprofen, an analgesic used for the treatment of pain, fever and inflammation. It completed the pivotal phase III trial to evaluate the safety and efficacy of its 12 hour CDT 600 milligram controlled release ibuprofen for the OTC market. In addition, the Company submitted its first abbreviated new drug application (ANDA) for its 12-hour pseudoephedrine product on August 5, 2008.

The Micron Group delves deeply into the world of drug discovery. Composed of companies based in the UK, the US, and South Africa -- including Micron Research, the group's flagship unit -- the group provides consulting services for pharmaceuticals research, development, and delivery companies. With expertise in Phase I-IV drug discovery trials, clinical research, data delivery, medical education, and medical communications, the group's services range from clinical development and research to marketing, strategic planning, and report publishing. The Micron Group also offers its SILK software for managing pharmaceutical R&D and marketing processes. Clients include Bristol-Myers Squibb and the World Health Organization.

ADVENTRX Pharmaceuticals, Inc. company was founded in 1995 is based in San Diego, California. ADVENTRX Pharmaceuticals, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing proprietary product candidates for the treatment of cancer. Its lead product candidates include ANX-530, a novel emulsion formulation of chemotherapy drug vinorelbine to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, as well as to treat advanced or metastatic breast cancer; and ANX-514, a novel emulsion formulation of the chemotherapy drug docetaxel for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers.

Neptune Technologies & Bioressources harvests krill (tiny deepwater crustaceans that resemble shrimp) from the ocean and processes it into value-added bioactive ingredients including polyunsaturated fatty acids and antioxidants. These 'Neptune Krill Oil'-based products are used in cosmetics and nutritional supplements as an alternative to vegetable oils. The company's Neptune Krill Aquatein is a marine protein concentrate also used in nutritional supplements. Neptune Technologies intends to penetrate the biopharmaceutical industry, using its marine oil extracts as a medicinal base.

Keryx Biopharmaceuticals, Inc. was founded in 1998 and is based in New York, New York. Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Its products under development include Zerenex, an oral iron-based compound is in Phase II clinical development for the treatment of hyperphosphatemia in patients with end-stage renal disease in the United States and Japan; and KRX-0401, an oral anti-cancer agent in Phase II clinical development that modulates Akt, and various other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation, and cell survival. Keryx Biopharmaceuticals has strategic alliances with AEterna Zentaris Inc.; Panion & BF Biotech, Inc.; Japan Tobacco Inc.; and Torii Pharmaceutical Co., Ltd. for the manufacture and commercialization of its products.

BioSpecifics Technologies Corp. company was founded in 1957 and is headquartered in Lynbrook, New York. BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase for multiple indications in the United States. The company has a development and license agreement with Auxilium Pharmaceuticals, Inc. for injectable collagenase known as XIAFLEX for clinical indications in dupuytren's disease, peyronie's disease, and frozen shoulder. The XIAFLEX is under phase IIb clinical trial for the treatment of peyronie's disease. BioSpecifics Technologies also focuses on the development of collagenase for various other clinical indications, including lipomas and cellulite.

Applied Genetic Technologies Corporation company was formed in 1999; funding partners include InterWest Partners, InterSouth Partners, and MedImmune Ventures. Applied Genetic Technologies Corporation (AGTC) applies itself to developing gene therapies for acquired and inherited genetic diseases. Its lead product is a treatment for Alpha One Antitrypsin Deficiency, which is an inherited cause of emphysema that is the most common hereditary disease in the Western World. Aside from causing lung disease in adults, it can also lead to liver disease in children. AGTC is also developing a treatment for Leber Congenital Amaurosis, which causes blindness, in collaboration with the universities of Florida and Pennsylvania, and Cornell University.

MiddleBrook Pharmaceuticals was founded in 1999 and is headquartered in Germantown, Maryland. MiddleBrook Pharmaceuticals, Inc., a pharmaceutical company, engages in the development and commercialization of anti-infective drug products in the United States. The company develops a proprietary delivery technology called PULSYS, which enables the pulsatile delivery, or delivery in rapid bursts, of drugs. Its product portfolio includes MOXATAG tablets for the treatment of pharyngitis and tonsillitis; and KEFLEX capsules for the treatment of skin and skin structure infections and upper respiratory tract infections. MiddleBrook Pharmaceuticals sells its products through specialty pharmaceutical distributors and wholesalers to physicians, hospitals, and pharmacies.

Cangene Corporation company makes plasma products known as hyperimmunes, which are antibody preparations and recombinant biopharmaceuticals made by introducing a gene in a host organism. Cangene's drugs are used to treat plasma-derived disorders, including the blood clotting disorder thrombocytopenic purpura and hemolytic disease of the newborn, which occurs when a fetus' blood type is incompatible with its mother's. Cangene has several approved products and is developing others, mainly in the areas of infectious disease and biodefense. Generic giant Apotex owns more than 80% of Cangene.

Micromet, Inc. (Micromet) is a biopharmaceutical company developing antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. Four of the Company's antibodies are in clinical trials, while the remainder of its product pipeline is in pre-clinical development. The Company’s BiTE antibody blinatumomab, known as MT103, is being evaluated in a phase II clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase I clinical trial for the treatment of patients with non-Hodgkin’s lymphoma (NHL). A second BiTE antibody, MT110, is being tested in a phase I clinical trial for the treatment of patients with solid tumors. MT110 binds to the epithelial cell adhesion molecule (EpCAM), which is over-expressed in many solid tumors.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.